Media contact Jennifer Huang Marketing Communications Manager, Asia PolyOne Corporation +86 21 50802923 jennifer.huang@avient.com Media Relations Contacts Company Officers

Commenting on the company’s outlook, Mr. The question and answer session will follow the company’s presentation and prepared remarks. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission. 6 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

The company noted that GAAP EPS includes special items (Attachment 3), which impacted EPS in both periods. There will be a question and answer session following the company’s presentation and prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. 6 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

The company will host a webcast at Investor Relations Contact: Giuseppe (Joe) Di Salvo, Vice President, Treasurer and Investor Relations, Avient Corporation, +1 440-930-1921, giuseppe.disalvo@avient.com; Media Contact: Kyle G. Investor Contacts

Under these circumstances, contact the Corporate Ethics Officer (ethics.officer@avient.com) or General Counsel (legal.officer@avient.com) immediately. Contact your Legal partner to request a due diligence review, and ensure you have received written approval prior to working with any agent or third party. An independent company receives all website and phone reports received by the Ethics Hotline and reports the information to the Corporate Ethics Officer.

Requirements: Skin contact colorant certified for ISO 10993 biocompatibility OnColor™ HC Plus, MEVOPUR® 5. Requirements: USP Class VI skin contact colorant for drug differentiation OnColor™ HC, MEVOPUR® 4 Button 5 Batch or SKU identifier Safety and trigger cap 6 CONCENTRATION 1 CONCENTRATION 2 CONCENTRATION 3 Patient Handling Age or certain disease states can severely limit patient dexterity making the self-administration of medication difficult and frustrating. Our company is a great place to work.

as applicable) 4.2.2 Customer Description 4.2.3 Manufacturer’s Product Code 4.2.4 Manufacturer's Lot Number 4.2.5 Quantity and Units (Example 25 lbs.) 4.2.6 Company Name 4.2.7 Date of Manufacture 4.2.8 Expiration Date (as applicable) 5.0 SUPPORTING DOCUMENTATION 5.1 Certification: Each shipment of product will be accompanied by a Certification that, at the time of shipment, the material conforms to the Product Specifications. 5.1.1 Certification document will include: 5.1.1.1 Customer Part Number 5.1.1.2 Customer Purchase Order Number 5.1.1.3 Customer Material Description 5.1.1.4 Manufacturer's Lot Number 5.1.1.5 Total quantity shipped (with units) 5.1.1.6 Test values (as applicable) 5.1.2 Certification will be sent with each product shipment, addressed to the Customer’s shipping location and/or electronically sent to appropriate Customer contact. 5.1.3 The Certification document may contain test values conducted by NEU on the product for those characteristics listed under certification. 5.2 Safety Data Sheets: A Safety Data Sheet will be made available upon request or may be available on NEU’s website. Such inquiries by NEU do not transfer supplier control responsibilities to NEU. 8.0 CHANGE NOTIFICATION 8.1 General Notification 8.1.1 NEU will notify the Customer of the following changes to all NEU compounded materials: 8.1.1.1 Product nomenclature 8.1.1.2 Product Specifications 8.1.1.3 Manufacturing site 8.1.2 All notifications will be given to the purchasing contact at the purchasing locations of the products supplied.

The question and answer session will follow the company’s presentation and prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission. 6 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

Third Quarter and Full Year 2021 Outlook Commenting on the company’s 2021 outlook, Mr. There will be a question and answer session following the company’s presentation and prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. 5 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

The Company noted it will provide more details on its 2021 outlook during the webcast scheduled for 9:00 a.m. There will be a question and answer session following the company’s presentation and prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. 6 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.